111 Stock Price, News & Analysis

111, Inc. (NASDAQ: YI) has announced a strategic partnership with Chugai Pharma China to advance healthcare in China through innovative digital solutions. This collaboration aims to establish a 'SMART Healthcare City' concept, enhancing the treatment accessibility for chronic diseases. As the first e-commerce company to form such a partnership with Chugai, 111 will leverage its technological strengths to improve healthcare delivery. Both companies intend to align with China's 'Healthy China 2030' initiative, which targets comprehensive chronic disease management for better patient outcomes.

111, Inc. (NASDAQ: YI) announced its participation in the Cantor Global Healthcare Conference, taking place virtually from September 27-30, 2021. Senior VP Tiffany ZhuGe will present an update on the Company and engage in one-on-one meetings with investors on September 27, 2021, at 4:40 PM ET. A live and archived webcast will be accessible on the Company’s Investor Relations website. 111, Inc. focuses on digitally connecting patients with healthcare services in China, providing a wide array of pharmaceutical and online healthcare services through its various platforms.

111, Inc. (NASDAQ: YI) announced a $10 million share repurchase program, which will be executed over the next twelve months to enhance shareholder value. The buyback will provide the company with flexibility to repurchase shares at prevailing market prices through various transactions. This strategic move is expected to positively impact the stock price and reflect the company's confidence in its future performance. The repurchases will be funded from the existing cash balance, showcasing the company's commitment to maximizing shareholder returns.

111, Inc. (NASDAQ: YI) announced an expansion of its partnership with Bayer Healthcare, enhancing their collaboration on drug commercialization in China. Building on their initial 2020 agreement, the companies will now cover more therapeutic areas, including diabetes and oncology, while leveraging 111's technology and extensive pharmacy network to improve patient education and outreach. Moreover, a digital content portal will be developed for online pharmacist training. This partnership aims to modernize healthcare delivery in China, offering a more integrated healthcare solution.

111, Inc. (NASDAQ: YI) will announce its second quarter 2021 unaudited financial results on August 27, 2021, before U.S. market opens. An earnings conference call will follow at 7:30 AM Eastern Time. Participants must register online to receive dial-in information. The call will be available for replay until September 4, 2021, and will also be accessible via a live and archived webcast on the company's Investor Relations page.

111, Inc. is a leading tech-enabled healthcare platform in China, facilitating access to pharmacies and healthcare services.

111, Inc. (NASDAQ: YI) has entered into a strategic cooperation agreement with Suzhou Zelgen Biopharmaceuticals to develop a virtual management platform for liver cancer patients in China. This initiative aims to integrate medical resources and provide online consultations, treatment options, and educational resources. Liver cancer is a major health concern, with around 410,000 new cases reported in 2020. Zelgen's drug, Zeprosyn®, recently received approval for treating unresectable hepatocellular carcinoma and will be available through this platform, enhancing patient access to innovative treatments.

111, Inc. (YI) reported Q1 2021 net revenues of RMB2.6 billion (US$396.0 million), up 64.7% year-over-year, with 89.0% growth after excluding pandemic-related items. Operating expenses increased 43.6% to RMB289.0 million (US$44.1 million), comprising 11.1% of revenues. Non-GAAP net loss decreased slightly to RMB109.3 million (US$16.7 million), or 4.2% of revenue, compared to 6.9% a year earlier. The company holds cash and equivalents of RMB1.2 billion (US$177.5 million). Looking ahead, YI forecasts Q2 2021 revenues between RMB2.92 billion and RMB3.08 billion, indicating an 80% to 90% annual growth.

111, Inc. (NASDAQ: YI), a leading tech-enabled healthcare platform in China, is set to announce its unaudited financial results for Q1 2021 on May 19, 2021. The report will be released before U.S. market opens, followed by an earnings conference call at 7:30 AM ET, allowing investors to engage directly with management. 111 provides consumers access to pharmaceuticals and healthcare services through its online platform and extensive offline pharmacy network.

111, Inc. (Nasdaq: YI) has partnered with Jianming Pharmaceutical Group to develop an online chronic disease management platform for hepatobiliary diseases in China. The initiative aims to enhance access to liver and gallbladder medications, starting in Fujian province and expanding nationally. With over 90 million hepatitis B cases and 13 million chronic hepatitis C cases in China, the platform seeks to address the lack of knowledge and resources available for these diseases. The collaboration leverages 111's tech capabilities and extensive pharmacy network, promoting efficient distribution and education on treatment options.